{"id":"ultra-long-gnrh-agonists","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents bind to GnRH receptors and provide extended pharmacological activity through modified formulations or delivery systems, resulting in continuous suppression of the hypothalamic-pituitary-gonadal axis. This leads to sustained reduction in sex hormone production (testosterone and estrogen), with effects lasting weeks to months per dose. The ultra-long duration distinguishes them from conventional GnRH agonists by reducing dosing frequency and improving patient compliance.","oneSentence":"Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:18.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (androgen deprivation therapy)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT06985186","phase":"PHASE4","title":"Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2025-06","conditions":"Adenomyosis of Uterus, Infertility Assisted Reproductive Technology","enrollment":162},{"nctId":"NCT05937490","phase":"PHASE4","title":"Adenomyosis and ART","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2023-03-27","conditions":"Adenomyosis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ultra-Long GnRH Agonists","genericName":"Ultra-Long GnRH Agonists","companyName":"University of Palermo","companyId":"university-of-palermo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release. Used for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}